167 related articles for article (PubMed ID: 38317080)
1. Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
Jamalzadeh S; Dai J; Lavikka K; Li Y; Jiang J; Huhtinen K; Virtanen A; Oikkonen J; Hietanen S; Hynninen J; Vähärautio A; Häkkinen A; Hautaniemi S
BMC Cancer; 2024 Feb; 24(1):173. PubMed ID: 38317080
[TBL] [Abstract][Full Text] [Related]
2. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
3. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.
Martins FC; Couturier DL; de Santiago I; Sauer CM; Vias M; Angelova M; Sanders D; Piskorz A; Hall J; Hosking K; Amirthanayagam A; Cosulich S; Carnevalli L; Davies B; Watkins TBK; Funingana IG; Bolton H; Haldar K; Latimer J; Baldwin P; Crawford R; Eldridge M; Basu B; Jimenez-Linan M; Mcpherson AW; McGranahan N; Litchfield K; Shah SP; McNeish I; Caldas C; Evan G; Swanton C; Brenton JD
Nat Commun; 2022 Oct; 13(1):6360. PubMed ID: 36289203
[TBL] [Abstract][Full Text] [Related]
4. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA
BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155
[TBL] [Abstract][Full Text] [Related]
5. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
6. Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis.
Song X; Ji J; Gleason KJ; Yang F; Martignetti JA; Chen LS; Wang P
Mol Cell Proteomics; 2019 Aug; 18(8 suppl 1):S52-S65. PubMed ID: 31227599
[TBL] [Abstract][Full Text] [Related]
7. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
8. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.
Mita H; Toyota M; Aoki F; Akashi H; Maruyama R; Sasaki Y; Suzuki H; Idogawa M; Kashima L; Yanagihara K; Fujita M; Hosokawa M; Kusano M; Sabau SV; Tatsumi H; Imai K; Shinomura Y; Tokino T
BMC Cancer; 2009 Jun; 9():198. PubMed ID: 19545448
[TBL] [Abstract][Full Text] [Related]
9. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
Cope L; Wu RC; Shih IeM; Wang TL
Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914
[TBL] [Abstract][Full Text] [Related]
10. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
11. Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors.
Kumar M; Bowers RR; Delaney JR
Cell Cycle; 2020 Nov; 19(22):3154-3166. PubMed ID: 33121339
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.
Nguyen MTN; Rajavuori A; Huhtinen K; Hietanen S; Hynninen J; Oikkonen J; Hautaniemi S
Biomed Pharmacother; 2023 Dec; 168():115630. PubMed ID: 37806091
[TBL] [Abstract][Full Text] [Related]
13. Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis.
Thiesen HJ; Steinbeck F; Maruschke M; Koczan D; Ziems B; Hakenberg OW
PLoS One; 2017; 12(5):e0176659. PubMed ID: 28486536
[TBL] [Abstract][Full Text] [Related]
14. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
[TBL] [Abstract][Full Text] [Related]
15. Histotype-specific copy-number alterations in ovarian cancer.
Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
18. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
Engler DA; Gupta S; Growdon WB; Drapkin RI; Nitta M; Sergent PA; Allred SF; Gross J; Deavers MT; Kuo WL; Karlan BY; Rueda BR; Orsulic S; Gershenson DM; Birrer MJ; Gray JW; Mohapatra G
PLoS One; 2012; 7(2):e30996. PubMed ID: 22355333
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
20. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
